Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acusphere Future Up In Air After Imagify Fails Before Advisory Panel

Executive Summary

Evolving trial design standards and miscommunication with the review division tripped up Acusphere's effort to bring Imagify to market, signaling to competitors in the space that FDA is raising the bar on contrast imaging agents
Advertisement

Related Content

King’s Cardiac Imaging Drug Binodenoson Gets Committee Review
Imagify gets “complete response”
Imagify gets “complete response”
REMS Cannot Rescue Imagify: Clear Product Benefit Needed To Convince FDA
REMS Cannot Rescue Imagify: Clear Product Benefit Needed To Convince FDA
Acusphere Left Unstable By FDA Panel Review; CEO Turns Ire On Panelists
Acusphere Left Unstable By FDA Panel Review; CEO Turns Ire On Panelists
Acusphere Left Unstable By FDA Panel Review; CEO Turns Ire On Panelists
Acusphere Reports Mixed Top-Line Phase III Results For Imagify
Advertisement
UsernamePublicRestriction

Register

PS050429

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel